- Home
- ASTI vs QLGN Comparison
ASTI vs QLGN Comparison
Compare ASTI & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTI
- QLGN
- Stock Information
- Founded
- ASTI 2005
- QLGN 1996
- Country
- ASTI United States
- QLGN United States
- Employees
- ASTI N/A
- QLGN N/A
- Industry
- ASTI Semiconductors
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ASTI Technology
- QLGN Health Care
- Exchange
- ASTI Nasdaq
- QLGN Nasdaq
- Market Cap
- ASTI 2.9M
- QLGN 2.8M
- IPO Year
- ASTI N/A
- QLGN N/A
- Fundamental
- Price
- ASTI $3.29
- QLGN $3.54
- Analyst Decision
- ASTI
- QLGN
- Analyst Count
- ASTI 0
- QLGN 0
- Target Price
- ASTI N/A
- QLGN N/A
- AVG Volume (30 Days)
- ASTI 6.4M
- QLGN 9.1K
- Earning Date
- ASTI 08-05-2025
- QLGN 08-13-2025
- Dividend Yield
- ASTI N/A
- QLGN N/A
- EPS Growth
- ASTI N/A
- QLGN N/A
- EPS
- ASTI N/A
- QLGN N/A
- Revenue
- ASTI $51,917.00
- QLGN N/A
- Revenue This Year
- ASTI N/A
- QLGN N/A
- Revenue Next Year
- ASTI N/A
- QLGN N/A
- P/E Ratio
- ASTI N/A
- QLGN N/A
- Revenue Growth
- ASTI N/A
- QLGN N/A
- 52 Week Low
- ASTI $1.10
- QLGN $2.85
- 52 Week High
- ASTI $12.00
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- ASTI 74.69
- QLGN 44.87
- Support Level
- ASTI $1.10
- QLGN $3.37
- Resistance Level
- ASTI $1.63
- QLGN $3.85
- Average True Range (ATR)
- ASTI 0.24
- QLGN 0.23
- MACD
- ASTI 0.06
- QLGN -0.03
- Stochastic Oscillator
- ASTI 66.67
- QLGN 34.29
About ASTI Ascent Solar Technologies Inc.
Ascent Solar Technologies Inc is engaged in the manufacturing, and selling of photovoltaic products (PV) solar modules that are flexible, durable, and possess attractive power-to-weight and power-to-area performance. The company is integrating its PV products into scalable and high-value markets such as agrivoltaics, aerospace, satellites, near-earth orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). Ascent is also working to expand its portable solar chargers, such as the XD-12. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.